Capoluongo, N.; Mascolo, A.; Bernardi, F.F.; Sarno, M.; Mattera, V.; di Flumeri, G.; Pustorino, B.; Spaterella, M.; Trama, U.; Capuano, A.;
et al. Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19. Pharmaceuticals 2023, 16, 1493.
https://doi.org/10.3390/ph16101493
AMA Style
Capoluongo N, Mascolo A, Bernardi FF, Sarno M, Mattera V, di Flumeri G, Pustorino B, Spaterella M, Trama U, Capuano A,
et al. Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19. Pharmaceuticals. 2023; 16(10):1493.
https://doi.org/10.3390/ph16101493
Chicago/Turabian Style
Capoluongo, Nicolina, Annamaria Mascolo, Francesca Futura Bernardi, Marina Sarno, Valentina Mattera, Giusy di Flumeri, Bruno Pustorino, Micaela Spaterella, Ugo Trama, Annalisa Capuano,
and et al. 2023. "Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19" Pharmaceuticals 16, no. 10: 1493.
https://doi.org/10.3390/ph16101493
APA Style
Capoluongo, N., Mascolo, A., Bernardi, F. F., Sarno, M., Mattera, V., di Flumeri, G., Pustorino, B., Spaterella, M., Trama, U., Capuano, A., & Perrella, A.
(2023). Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19. Pharmaceuticals, 16(10), 1493.
https://doi.org/10.3390/ph16101493
